Health Catalyst downgraded by Guggenheim
$HCAT
Computer Software: Programming Data Processing
Technology
Guggenheim downgraded Health Catalyst from Buy to Neutral
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/9/2025 | Outperform → In-line | Evercore ISI | |
| 1/8/2025 | $9.00 | Sector Weight → Overweight | KeyBanc Capital Markets |
| 4/10/2024 | Overweight → Sector Weight | KeyBanc Capital Markets | |
| 1/3/2024 | $14.00 | Overweight | Barclays |
| 1/3/2024 | $11.00 | In-line → Outperform | Evercore ISI |
| 12/13/2023 | $14.00 → $11.00 | Neutral → Overweight | JP Morgan |
| 11/13/2023 | $12.00 → $11.00 | Neutral → Overweight | Piper Sandler |
| 8/1/2023 | $16.00 | Overweight | Cantor Fitzgerald |
4 - Health Catalyst, Inc. (0001636422) (Issuer)